New Therapeutic Targets in Non–Small Cell Lung Cancer: KRAS G12C
On February 3, 2021, OncLive® brought together a group of oncologists who specialize in the treatment of lung cancer to participate in a virtual workshop to discuss the emerging treatment landscape of targeted therapies in NSCLC. This article summarizes key data about KRAS G12C as a therapeutic target as well as insights from stakeholder discussions regarding this topic.
EP: 1.Dr. Boyle on the Role of Concurrent Molecular Testing in Lung Cancer
EP: 2.Dr. Longshore on Key Molecular Markers in Metastatic Lung Cancer
EP: 3.Dr. Spira on the Role of Broad Molecular Testing in Lung Cancer
EP: 4.Dr. Levy on the Importance of Testing for KRAS Mutations in Lung Cancer
EP: 5.Dr. Hanna on Approaching Biomarker Testing in Lung Cancer
EP: 6.Dr. Longshore on Comprehensive Vs Single-Gene Molecular Testing in Lung Cancer
EP: 7.Dr. Boyle on Approaching Biomarker Testing in Lung Cancer
Now Viewing
EP: 8.New Therapeutic Targets in Non–Small Cell Lung Cancer: KRAS G12C
Related Videos
Related Content
